FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Announced US FDA approval of ORZEYFUL for narcolepsy type 1 and preparing follow-up steps for its US launch

  • The company announced US FDA approval of ORZEYFUL for adults with narcolepsy type 1. Source

Roles often seen at this stageRegulatory affairs · Sales & marketing · Medical & MSL

Companies at the same stage and their people flow →

← Company library
Japan / Company briefSources checked 2026-10-03

Takeda Pharmaceutical

武田薬品工業

Official name · 武田薬品工業株式会社

An R&D-driven biopharmaceutical company engaged in pharmaceutical research, manufacturing, sales and international trade.

ORZEYFUL / oveporexton

Approved

Announced FDA approval for adults with narcolepsy type 1; availability was stated to follow DEA scheduling.

Completion reported

Announced US approval of oral orexin 2 receptor agonist ORZEYFUL.

Recruitment program

2027年入社 研究技術職

Current availability unconfirmed

Observed 2026-10-03 · Application window 2026-07-27 — Date unconfirmed

Work
Unconfirmed — Detailed requirements were not confirmed in the reviewed official material.
Experience & requirements
Unconfirmed — Detailed requirements were not confirmed in the reviewed official material.
Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 会社概要 ↗武田薬品 · Published Date unconfirmed · Sources checked 2026-10-03
  2. ORZEYFUL approved for narcolepsy type 1 ↗Takeda · Published 2026-08-05 · Sources checked 2026-10-03
  3. 採用情報 ↗武田薬品 · Published Date unconfirmed · Sources checked 2026-10-03